logo-loader
viewScancell Holdings PLC

Scancell Hlds - Director Award of Share Options

RNS Number : 0029Y
Scancell Holdings Plc
04 September 2020
 

04 September 2020

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Director Award of Share Options

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces that on 30 July 2020 it has granted 3,850,000 share options to acquire ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") to Professor Lindy Durrant and 2,880,000 share options to acquire ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") to Dr Richard Goodfellow. These share options will expire on 30 July 2023 and replace previously issued share options that expired on 14 July 2020.

 

The Options have an exercise price of 4.5 pence each (the same price as the expired shares) and will vest twelve months from the date of Grant.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Professor Lindy Durrant

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Scancell Holdings plc

b)

LEI

2138008RXEG856SNP666

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options to acquire Ordinary Shares

b)

Nature of the transaction

Grant of options to acquire Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

4.5 pence

3,850,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

3 September 2020

f)

Place of the transaction

Outside a trading venue

 

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Dr Richard Goodfellow

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Scancell Holdings plc

b)

LEI

2138008RXEG856SNP666

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Options to acquire Ordinary Shares

b)

Nature of the transaction

Grant of options to acquire Ordinary Shares

c)

Price(s) and volume(s)

Price(s)

Volume(s)

4.5 pence

2,880,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A (Single transaction)

e)

Date of the transaction

3 September 2020

f)

Place of the transaction

Outside a trading venue

 

 

 

- ENDS -

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

For more information, please contact:

 

Scancell Holdings plc

+44 (0)20 3727 1000

Dr John Chiplin, Chairman


Dr Cliff Holloway, CEO




Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: James Stearns




FTI Consulting

+44 (0)20 3727 1000

Simon Conway


Natalie Garland-Collins


 

 

Notes for Editors

 

About Scancell

 

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

 

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

 

·    SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·    SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

 

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

 

·    Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

 

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

 

In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against SARS-Cov-2, the virus that causes COVID-19. The Company believes this combined T cell and antibody approach should give more potent and long-lasting responses, ultimately leading to better protection.

 

For further details, please see our website:  www.scancell.co.uk 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFIRALIVIII

Quick facts: Scancell Holdings PLC

Price: 14.875

Market: LSE
Market Cap: £109.87 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 on back foot over fears it could take years to find...

Headlines from the Proactive UK newsroom. The FTSE 100 is on the back foot on fears it might take years to find an effective vaccine or treatment against coronavirus. The blue-chip index dropped 70 points to 5,755. Overnight, US firm Gilead Sciences terminated a highly anticipated Chinese...

on 24/4/20